Karen Pendergrass, Standards Team

This study identifies global microbiota signatures in BS patients, revealing distinct microbial imbalances that differentiate them from healthy controls. Key findings include a 2-fold increase in the Bacteroidetes ratio, reduced Bifidobacterium and Faecalibacterium populations, and significant shifts in methanogens. These alterations suggest potential diagnostic markers and therapeutic targets for BS.

This study reveals that altered microbiota and elevated organic acids in BS patients correlate with increased symptom severity, poorer quality of life, and heightened negative emotions. The findings suggest that microbial shifts leading to increased acetic and propionic acid production play a critical role in the pathophysiology of BS.

This study reveals that BS patients have significantly lower bifidobacteria counts in both fecal and duodenal samples compared to healthy controls. The marked reduction in Bifidobacterium catenulatum levels suggests a critical link to gut dysbiosis, impaired mucosal integrity, and potential contributions to symptom severity in BS subtypes.